Digoxin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Atrial fibrillation

• Diltiazem ER
• Metoprolol tartrate
• Warfarin

Also listed for Atrial Fibrillation (Stroke Prevention)

• Warfarin Sodium
• Amiodarone
• Apixaban
• Dabigatran
• Metoprolol

Other medications in Heart & Cardiovascular

• Diltiazem
• Dobutamine
• Dronedarone
• Empagliflozin (HF)
• Enalapril
• Eplerenone
• Epoprostenol
• Eprosartan

About Digoxin

Digoxin is a long-standing medication vital for managing certain heart conditions, helping millions lead healthier lives. At TheDrugClub, we believe that essential heart medications like digoxin should be accessible and affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Digoxin is approved for (FDA label)

Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.

Source: Read the full FDA label on DailyMed. Label effective date: July 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Digoxin (FDA label)

125 mcg tablets are yellow, round, scored tablets imprinted with “JSP-544”. 250 mcg tablets are white, round, scored tablets imprinted with “JSP-545”. Scored Tablets 125 and 250 mcg

Source: FDA prescribing information (DailyMed). Set ID: e61d2108-d871-44c0-b12a-2e61fbb56967. SPL document ID: 11443c80-fca0-4c9e-be13-a5f92717a715. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Digoxin (FDA label)

The following adverse reactions are included in more detail in the Warnings and Precautions section of the label: Cardiac arrhythmias [see Warnings and Precautions (5.1 , 5.2 )] Digoxin Toxicity [see Warnings and Precautions (5.3) ] The overall incidence of adverse reactions with digoxin has been reported as 5-20%, with 15-20% of adverse events considered serious.

Source: FDA prescribing information (DailyMed). Set ID: e61d2108-d871-44c0-b12a-2e61fbb56967. SPL document ID: 11443c80-fca0-4c9e-be13-a5f92717a715. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Digoxin (FDA label)

Digoxin is contraindicated in patients with: Ventricular fibrillation [see Warnings and Precautions (5.1)] Known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. Ventricular fibrillation. ( 4 ) Known hypersensitivity to digoxin or other forms of digitalis. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: e61d2108-d871-44c0-b12a-2e61fbb56967. SPL document ID: 11443c80-fca0-4c9e-be13-a5f92717a715. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Digoxin (FDA label)

Risk of rapid ventricular response leading to ventricular fibrillation in patients with AV accessory pathway. ( 5.1 ) Risk of advanced or complete heart block in patients with sinus node disease and AV block. ( 5.2 ) Digoxin toxicity: Indicated by nausea, vomiting, visual disturbances, and cardiac arrhythmias. Advanced age, low body weight, impaired renal function and electrolyte abnormalities predispose to toxicity. ( 5.3 ) Risk of ventricular arrhythmias during electrical cardioversion. ( 5.4 ) Not recommended in patients with acute myocardial infarction. ( 5.5 ) Avoid digoxin in patients with myocarditis. ( 5.6 ) 5.1 Ventricular Fibrillation in Patients With Accessory AV Pathway (Wolff-Parkinson- White Syndrome) Patients with Wolff-Parkinson-White syndrome who develop atrial fibrillation are at high risk of ventricular fibrillation.

Source: FDA prescribing information (DailyMed). Set ID: e61d2108-d871-44c0-b12a-2e61fbb56967. SPL document ID: 11443c80-fca0-4c9e-be13-a5f92717a715. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Digoxin (FDA label)

Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin. Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information. PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. ( 7.1 ) The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information. ( 7.2 , 7.3 , 12.3 ) 7.1 P-Glycoprotein (PGP) Inducers/Inhibitors Digoxin is a substrate of P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary–intestinal secretion.

Source: FDA prescribing information (DailyMed). Set ID: e61d2108-d871-44c0-b12a-2e61fbb56967. SPL document ID: 11443c80-fca0-4c9e-be13-a5f92717a715. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.